ASH 2018 | Pioneering CAR-Macrophage therapies for solid tumours

In this interview, Saar Gill, MD, PhD, from the University of Pennsylvania, Philadelphia, PA., introduces CARISMA Therapeutics, a biotechnology company pioneering the CAR-Macrophage (CARMA) platform, a novel technology aiming to combine antigen recognition with the effector function of macrophages. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Gill reveals the importance in the translation of observations in the lab to the clinical setting, a key challenge that the company hopes to overcome.